Last reviewed · How we verify
SKLB1028
SKLB1028 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and survival.
SKLB1028 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and survival. Used for Solid tumors (Phase 3 development).
At a glance
| Generic name | SKLB1028 |
|---|---|
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Drug class | Multi-kinase inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SKLB1028 inhibits receptor tyrosine kinases and intracellular signaling pathways critical for tumor growth. The drug is designed to block multiple kinase targets simultaneously, potentially providing broader anti-cancer activity. It has been developed primarily for solid tumors in early clinical development.
Approved indications
- Solid tumors (Phase 3 development)
Common side effects
Key clinical trials
- SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (PHASE1, PHASE2)
- A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects (PHASE1)
- A Dose Escalation and Food Effect Study of SKLB1028 in Healthy Subjects (PHASE1)
- A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated (PHASE3)
- A Study of SKLB1028 in Patients With Advanced Solid Tumor (PHASE1)
- A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy Subjects (PHASE1)
- A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects (PHASE1)
- A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SKLB1028 CI brief — competitive landscape report
- SKLB1028 updates RSS · CI watch RSS
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. portfolio CI